Trial
NCT03029832
A Study of MOXR0916 in Combination With Atezolizumab Versus Atezolizumab Alone in Participants With Untreated Locally Advanced or Metastatic Urothelial Carcinoma Who Are Ineligible for Cisplatin-Based Therapy
Phase IITERMINATEDOPERATIONALConfidence: HIGH
Sponsor
Genentech, Inc.
Collaborators
—
Condition
Urothelial Carcinoma
Intervention
MOXR0916
Why stopped
The study was prematurely terminated due to slow patient accrual and discontinuation of clinical development of MOXR0916 due to Sponsor's strategic priorities.
Provenance
Dataset: 2026-07-02 • Source: ClinicalTrials.gov API v2 • Last update: 2019-05-31